Cost savings associated with filling a 3-month supply of prescription medicines
- PMID: 19905039
- DOI: 10.1007/BF03256159
Cost savings associated with filling a 3-month supply of prescription medicines
Abstract
Background: Many patients are burdened by prescription costs, and patients, providers and policy makers may attempt to reduce these costs by substituting 3-month for 1-month supplies of medicines.
Objectives: To measure the difference in out-of-pocket and total costs among patients receiving different quantities of the same prescription drug used to treat a chronic condition, and to examine patient and health system characteristics associated with the use of a 3-month supply.
Methods: Data were pooled from the 2000-5 Medical Expenditure Panel Survey, a nationally representative survey of the US non-institutionalized civilian population, to compare prescription drug expenditures for medicines dispensed as both 3-month and 1-month supplies. Logistic regression was used to model correlates associated with 3-month use. The main outcome measures were the mean monthly out-of-pocket and total costs expressed in year 2005 values.
Results: Forty-four percent of prescriptions examined were dispensed as 3-month supplies. The average (95% CI) monthly total and out-of-pocket costs for a 1-month supply were $US42.72 (42.01, 43.42) and $US20.44 (19.99, 20.89), respectively, while the corresponding monthly costs for a 3-month supply were $US37.95 (37.26, 38.64) and $US15.10 (14.68, 15.53). After adjustment for potential confounders, this represented a 29% decrease in out-of-pocket costs and an 18% decrease in total prescription costs through the use of a 3-month rather than a 1-month supply. Eighty percent of patients achieved some cost savings from a 3-month supply and there was considerable variation in the amount saved. There were no marked differences in the characteristics of individuals using 3-month versus 1-month supplies.
Conclusions: Although such opportunities are not universally available, these findings quantify the cost savings that patients in the US can achieve through filling larger quantities of a prescription for a chronic condition.
Similar articles
-
Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.Am J Hypertens. 2008 May;21(5):509-13. doi: 10.1038/ajh.2008.31. Epub 2008 Mar 20. Am J Hypertens. 2008. PMID: 18437141
-
Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.JAMA. 2003 Jul 9;290(2):222-7. doi: 10.1001/jama.290.2.222. JAMA. 2003. PMID: 12851277
-
Effects of Real-time Prescription Benefit Recommendations on Patient Out-of-Pocket Costs: A Cluster Randomized Clinical Trial.JAMA Intern Med. 2022 Nov 1;182(11):1129-1137. doi: 10.1001/jamainternmed.2022.3946. JAMA Intern Med. 2022. PMID: 36094537 Free PMC article.
-
Choices in prescription-drug benefit programs: mail versus community pharmacy services.Milbank Q. 1990;68(1):29-51. Milbank Q. 1990. PMID: 2215427 Review.
-
Comparison of prescription reimbursement methodologies in Japan and the United States.J Am Pharm Assoc (2003). 2003 Jul-Aug;43(4):519-26. doi: 10.1331/154434503322226275. J Am Pharm Assoc (2003). 2003. PMID: 12952317 Review.
Cited by
-
Impact of issuing longer- versus shorter-duration prescriptions: a systematic review.Br J Gen Pract. 2018 Apr;68(669):e286-e292. doi: 10.3399/bjgp18X695501. Epub 2018 Mar 12. Br J Gen Pract. 2018. PMID: 29530921 Free PMC article.
-
Retrospective, multicohort analysis of the Clinical Practice Research Datalink (CPRD) to determine differences in the cost of medication wastage, dispensing fees and prescriber time of issuing either short (<60 days) or long (≥60 days) prescription lengths in primary care for common, chronic conditions in the UK.BMJ Open. 2017 Dec 4;7(12):e019382. doi: 10.1136/bmjopen-2017-019382. BMJ Open. 2017. PMID: 29208621 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
